240 related articles for article (PubMed ID: 22806893)
1. Role of SHP2 phosphatase in KIT-induced transformation: identification of SHP2 as a druggable target in diseases involving oncogenic KIT.
Mali RS; Ma P; Zeng LF; Martin H; Ramdas B; He Y; Sims E; Nabinger S; Ghosh J; Sharma N; Munugalavadla V; Chatterjee A; Li S; Sandusky G; Craig AW; Bunting KD; Feng GS; Chan RJ; Zhang ZY; Kapur R
Blood; 2012 Sep; 120(13):2669-78. PubMed ID: 22806893
[TBL] [Abstract][Full Text] [Related]
2. KIT's ship comes in.
Braun BS
Blood; 2012 Sep; 120(13):2541-2. PubMed ID: 23019203
[No Abstract] [Full Text] [Related]
3. Role of intracellular tyrosines in activating KIT-induced myeloproliferative disease.
Ma P; Mali RS; Martin H; Ramdas B; Sims E; Kapur R
Leukemia; 2012 Jul; 26(7):1499-1506. PubMed ID: 22297723
[TBL] [Abstract][Full Text] [Related]
4. The protein tyrosine phosphatase, Shp2, positively contributes to FLT3-ITD-induced hematopoietic progenitor hyperproliferation and malignant disease in vivo.
Nabinger SC; Li XJ; Ramdas B; He Y; Zhang X; Zeng L; Richine B; Bowling JD; Fukuda S; Goenka S; Liu Z; Feng GS; Yu M; Sandusky GE; Boswell HS; Zhang ZY; Kapur R; Chan RJ
Leukemia; 2013 Feb; 27(2):398-408. PubMed ID: 23103841
[TBL] [Abstract][Full Text] [Related]
5. Kit-Shp2-Kit signaling acts to maintain a functional hematopoietic stem and progenitor cell pool.
Zhu HH; Ji K; Alderson N; He Z; Li S; Liu W; Zhang DE; Li L; Feng GS
Blood; 2011 May; 117(20):5350-61. PubMed ID: 21450902
[TBL] [Abstract][Full Text] [Related]
6. Requirement for p85alpha regulatory subunit of class IA PI3K in myeloproliferative disease driven by an activation loop mutant of KIT.
Munugalavadla V; Sims EC; Chan RJ; Lenz SD; Kapur R
Exp Hematol; 2008 Mar; 36(3):301-8. PubMed ID: 18179858
[TBL] [Abstract][Full Text] [Related]
7. Genetic and pharmacologic evidence implicating the p85 alpha, but not p85 beta, regulatory subunit of PI3K and Rac2 GTPase in regulating oncogenic KIT-induced transformation in acute myeloid leukemia and systemic mastocytosis.
Munugalavadla V; Sims EC; Borneo J; Chan RJ; Kapur R
Blood; 2007 Sep; 110(5):1612-20. PubMed ID: 17483298
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic KIT-induced aggressive systemic mastocytosis requires SHP2/PTPN11 phosphatase for disease progression in mice.
Sharma N; Everingham S; Zeng LF; Zhang ZY; Kapur R; Craig AW
Oncotarget; 2014 Aug; 5(15):6130-41. PubMed ID: 25026279
[TBL] [Abstract][Full Text] [Related]
9. Shp2 function in hematopoietic stem cell biology and leukemogenesis.
Nabinger SC; Chan RJ
Curr Opin Hematol; 2012 Jul; 19(4):273-9. PubMed ID: 22504523
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic kit triggers Shp2/Erk1/2 pathway to down-regulate the pro-apoptotic protein Bim and to promote apoptosis resistance in leukemic cells.
Selimoglu-Buet D; Gallais I; Denis N; Guillouf C; Moreau-Gachelin F
PLoS One; 2012; 7(11):e49052. PubMed ID: 23145067
[TBL] [Abstract][Full Text] [Related]
11. SHP2 is required for BCR-ABL1-induced hematologic neoplasia.
Gu S; Sayad A; Chan G; Yang W; Lu Z; Virtanen C; Van Etten RA; Neel BG
Leukemia; 2018 Jan; 32(1):203-213. PubMed ID: 28804122
[TBL] [Abstract][Full Text] [Related]
12. Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1.
Gu S; Chan WW; Mohi G; Rosenbaum J; Sayad A; Lu Z; Virtanen C; Li S; Neel BG; Van Etten RA
Blood; 2016 Apr; 127(14):1803-13. PubMed ID: 26773044
[TBL] [Abstract][Full Text] [Related]
13. A germline gain-of-function mutation in Ptpn11 (Shp-2) phosphatase induces myeloproliferative disease by aberrant activation of hematopoietic stem cells.
Xu D; Wang S; Yu WM; Chan G; Araki T; Bunting KD; Neel BG; Qu CK
Blood; 2010 Nov; 116(18):3611-21. PubMed ID: 20651068
[TBL] [Abstract][Full Text] [Related]
14. The PI3-kinase isoform p110δ is essential for cell transformation induced by the D816V mutant of c-Kit in a lipid-kinase-independent manner.
Sun J; Mohlin S; Lundby A; Kazi JU; Hellman U; Påhlman S; Olsen JV; Rönnstrand L
Oncogene; 2014 Nov; 33(46):5360-9. PubMed ID: 24213578
[TBL] [Abstract][Full Text] [Related]
15. Protein-tyrosine phosphatase Shp2 positively regulates macrophage oxidative burst.
Li XJ; Goodwin CB; Nabinger SC; Richine BM; Yang Z; Hanenberg H; Ohnishi H; Matozaki T; Feng GS; Chan RJ
J Biol Chem; 2015 Feb; 290(7):3894-909. PubMed ID: 25538234
[TBL] [Abstract][Full Text] [Related]
16. Cotargeting signaling pathways driving survival and cell cycle circumvents resistance to Kit inhibitors in leukemia.
Buet D; Gallais I; Lauret E; Denis N; Lombard B; Guillonneau F; Kosmider O; Loew D; Dusanter-Fourt I; Guillouf C; Mayeux P; Moreau-Gachelin F
Blood; 2012 May; 119(18):4228-41. PubMed ID: 22438255
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1.
Piao X; Paulson R; van der Geer P; Pawson T; Bernstein A
Proc Natl Acad Sci U S A; 1996 Dec; 93(25):14665-9. PubMed ID: 8962111
[TBL] [Abstract][Full Text] [Related]
18. SH2 domain-containing phosphatase 2 is a critical regulator of connective tissue mast cell survival and homeostasis in mice.
Sharma N; Kumar V; Everingham S; Mali RS; Kapur R; Zeng LF; Zhang ZY; Feng GS; Hartmann K; Roers A; Craig AW
Mol Cell Biol; 2012 Jul; 32(14):2653-63. PubMed ID: 22566685
[TBL] [Abstract][Full Text] [Related]
19. Constitutive activation of SHP2 in mice cooperates with ICSBP deficiency to accelerate progression to acute myeloid leukemia.
Konieczna I; Horvath E; Wang H; Lindsey S; Saberwal G; Bei L; Huang W; Platanias L; Eklund EA
J Clin Invest; 2008 Mar; 118(3):853-67. PubMed ID: 18246201
[TBL] [Abstract][Full Text] [Related]
20. E3 ligase-defective Cbl mutants lead to a generalized mastocytosis and myeloproliferative disease.
Bandi SR; Brandts C; Rensinghoff M; Grundler R; Tickenbrock L; Köhler G; Duyster J; Berdel WE; Müller-Tidow C; Serve H; Sargin B;
Blood; 2009 Nov; 114(19):4197-208. PubMed ID: 19734451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
